Hospital
Memorial Medical Center
Memorial Medical Center was paid $3.13M by Medicaid between Jan 2018 and Jun 2020, across 167 billing codes. Its largest line is 97110, Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion — 39% of everything it billed.
33Billing provider infoMEMORIAL MEDICAL CENTER
SPRINGFIELD, IL 62781
SPRINGFIELD, IL 62781
33aNPI1427181882assigned 03/14/2007
33bProvider typeGeneral Acute Care Hospital
28Total paid$3.13M
24GClaims251,201
24DCodes billed167
24AFirst – last monthJan 2018 – Jun 2020
Compared with peers
Next to other General Acute Care Hospital providers in Illinois
Rank by total paid#12 of 129
Median peer was paid$547K
This provider vs. median5.7×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 76,768 | $956K | |
| 2019 | 120,598 | $1.46M | |
| 2020 | 53,835 | $717K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 39% | 14,139 | 3,775 | $1.23M |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 11% | 18,368 | 17,165 | $342K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 8.1% | 7,813 | 7,077 | $254K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 3.0% | 1,563 | 1,318 | $95K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 3.0% | 984 | 819 | $94K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 2.8% | 6,295 | 5,845 | $87K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 2.8% | 6,331 | 5,875 | $86K |
| 97162 | 2.5% | 968 | 795 | $77K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 2.2% | 5,163 | 1,682 | $69K |
| 97161 | 1.9% | 789 | 615 | $60K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.9% | 3,080 | 2,873 | $60K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 1.7% | 2,498 | 2,266 | $53K |
155 more codes
| 80053 | Comprehensive metabolic panel | 1.6% | 17,374 | $51K |
| 84443 | Thyroid stimulating hormone (TSH) | 1.6% | 8,739 | $50K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 1.4% | 1,705 | $43K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 2,783 | $30K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 8,785 | $27K |
| 87634 | <1% | 2,029 | $22K | |
| 87480 | <1% | 4,635 | $21K | |
| 87510 | <1% | 4,619 | $21K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 16,134 | $20K |
| 86480 | <1% | 673 | $15K | |
| 97163 | <1% | 158 | $14K | |
| 87522 | Neg quan hep c or qual rna | <1% | 669 | $13K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 4,675 | $13K |
| 88142 | <1% | 5,320 | $13K | |
| 87186 | <1% | 3,131 | $11K | |
| 87660 | <1% | 4,624 | $11K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,165 | $11K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,349 | $10K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 1,152 | $10K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 280 | $10K |
| 82607 | <1% | 3,006 | $9K | |
| 87653 | <1% | 418 | $9K | |
| 80061 | Lipid panel | <1% | 7,208 | $8K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 3,672 | $8K |
| 92610 | <1% | 582 | $7K | |
| 86780 | <1% | 1,730 | $7K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 360 | $6K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 4,887 | $6K |
| 87077 | <1% | 621 | $6K | |
| 84403 | <1% | 593 | $6K | |
| 85027 | <1% | 4,278 | $5K | |
| 84466 | <1% | 2,660 | $5K | |
| 80074 | <1% | 513 | $5K | |
| 86803 | <1% | 1,233 | $5K | |
| 87088 | <1% | 1,246 | $4K | |
| 81025 | <1% | 5,782 | $4K | |
| 86038 | <1% | 1,018 | $4K | |
| 82728 | <1% | 2,985 | $4K | |
| 85610 | <1% | 2,897 | $4K | |
| 81003 | <1% | 7,055 | $4K | |
| 87536 | <1% | 98 | $4K | |
| 92611 | <1% | 248 | $3K | |
| 81001 | <1% | 4,913 | $3K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 107 | $3K |
| 84439 | <1% | 1,778 | $3K | |
| 97165 | <1% | 275 | $3K | |
| 84153 | <1% | 720 | $3K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 371 | $3K |
| 88342 | <1% | 441 | $3K | |
| 83540 | <1% | 2,668 | $3K | |
| 73630 | <1% | 208 | $3K | |
| 72100 | <1% | 247 | $3K | |
| 92523 | <1% | 149 | $3K | |
| 83655 | <1% | 548 | $3K | |
| 87070 | <1% | 1,367 | $2K | |
| 73130 | <1% | 251 | $2K | |
| 84702 | <1% | 761 | $2K | |
| 87340 | <1% | 719 | $2K | |
| 82746 | <1% | 1,020 | $2K | |
| 74230 | <1% | 158 | $2K | |
| 83735 | <1% | 1,517 | $2K | |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 46 | $2K |
| 86787 | <1% | 382 | $2K | |
| 86140 | <1% | 1,572 | $1K | |
| 87493 | <1% | 71 | $1K | |
| 80076 | <1% | 607 | $1K | |
| 82043 | <1% | 1,571 | $1K | |
| 83516 | <1% | 448 | $1K | |
| 87338 | <1% | 146 | $1K | |
| 86431 | <1% | 713 | $1K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 147 | $993.20 |
| 87205 | <1% | 1,373 | $991.36 | |
| 85652 | <1% | 1,812 | $982.20 | |
| 84550 | <1% | 935 | $922.22 | |
| 86003 | <1% | 95 | $875.14 | |
| 83001 | <1% | 155 | $862.35 | |
| 82570 | <1% | 586 | $800.19 | |
| 80069 | <1% | 318 | $764.43 | |
| 83615 | <1% | 618 | $740.83 | |
| 82105 | <1% | 150 | $664.49 | |
| 83880 | <1% | 136 | $645.87 | |
| 83690 | <1% | 479 | $645.58 | |
| 86308 | <1% | 531 | $625.32 | |
| 82962 | <1% | 1,074 | $582.92 | |
| 86706 | <1% | 209 | $574.84 | |
| 73030 | <1% | 51 | $573.01 | |
| 84270 | <1% | 191 | $545.92 | |
| 86200 | <1% | 216 | $536.22 | |
| 73562 | <1% | 61 | $501.85 | |
| 84146 | <1% | 154 | $473.02 | |
| 83970 | <1% | 53 | $456.30 | |
| 80164 | <1% | 181 | $442.45 | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 16 | $429.90 |
| 97167 | <1% | 42 | $405.79 | |
| 86850 | <1% | 260 | $396.38 | |
| 88307 | <1% | 19 | $391.22 | |
| 82550 | <1% | 362 | $390.64 | |
| 82533 | <1% | 70 | $386.35 | |
| 82248 | <1% | 336 | $379.99 | |
| 87427 | <1% | 84 | $376.97 | |
| 80081 | <1% | 14 | $358.79 | |
| 74018 | <1% | 40 | $357.62 | |
| 86901 | <1% | 290 | $345.12 | |
| 87252 | <1% | 102 | $338.29 | |
| 87902 | <1% | 20 | $327.04 | |
| 88312 | <1% | 31 | $292.74 | |
| 82140 | <1% | 126 | $286.41 | |
| 84156 | <1% | 575 | $259.07 | |
| 87300 | <1% | 187 | $255.66 | |
| 85730 | <1% | 207 | $252.07 | |
| 86900 | <1% | 290 | $247.87 | |
| 82150 | <1% | 268 | $247.10 | |
| 80055 | <1% | 59 | $245.06 | |
| 86762 | <1% | 138 | $232.41 | |
| 87081 | <1% | 168 | $230.44 | |
| 86360 | <1% | 97 | $222.88 | |
| 87449 | <1% | 79 | $221.27 | |
| 83721 | <1% | 72 | $197.30 | |
| 87254 | <1% | 81 | $187.58 | |
| 82785 | <1% | 98 | $185.46 | |
| 87260 | <1% | 30 | $170.60 | |
| 85018 | <1% | 320 | $160.26 | |
| 80178 | <1% | 133 | $154.63 | |
| 85014 | <1% | 315 | $137.57 | |
| 82947 | <1% | 202 | $134.42 | |
| 87110 | <1% | 28 | $131.07 | |
| 87280 | <1% | 30 | $124.55 | |
| 87276 | <1% | 30 | $116.91 | |
| 86235 | <1% | 17 | $109.23 | |
| 87045 | <1% | 71 | $95.70 | |
| 86359 | <1% | 84 | $89.98 | |
| 82784 | <1% | 18 | $88.51 | |
| 83020 | <1% | 52 | $83.93 | |
| 87275 | <1% | 30 | $68.75 | |
| 86703 | <1% | 23 | $58.44 | |
| 86708 | <1% | 37 | $55.69 | |
| 82274 | <1% | 12 | $54.09 | |
| 87279 | <1% | 27 | $50.00 | |
| 86160 | <1% | 12 | $44.99 | |
| 83002 | <1% | 39 | $34.85 | |
| 82950 | <1% | 16 | $25.09 | |
| 84100 | <1% | 29 | $20.97 | |
| 84480 | <1% | 14 | $18.99 | |
| 85045 | <1% | 34 | $16.61 | |
| 82247 | <1% | 18 | $13.80 | |
| 86765 | <1% | 15 | $11.97 | |
| 82040 | <1% | 27 | $11.01 | |
| 84481 | <1% | 27 | $6.59 | |
| 84460 | <1% | 25 | $1.74 | |
| 80349 | 0% | 372 | $0.00 | |
| 86592 | 0% | 15 | $0.00 | |
| 80346 | 0% | 138 | $0.00 | |
| 80361 | 0% | 390 | $0.00 | |
| 80347 | 0% | 49 | $0.00 | |
| 80373 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialROSZHART, JAMESON (PRESIDENT & CEO)
| Provider | Location | Paid |
|---|---|---|
| Memorial Medical Center | Springfield, IL | $5K |
| Memorial Medical Center | Springfield, IL | $369.00 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.